The future direction of radiopharmaceutical development

Philip J. Blower

doi:10.1007/978-3-319-28624-2_19

The future direction of radiopharmaceutical development

Philip J. Blower^*

^*Corresponding author for this work

Imaging Chemistry & Biology

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

1 Citation (Scopus)

183 Downloads (Pure)

Abstract

The first use in humans of 24Na-sodium chloride by Hamilton and Stone in 1936 began a story in which 131I-iodide became established for treating thyroid disease and radionuclide imaging became routine in hospitals. Later a range of 99mTc-radiotracers quickly became available and they were easily synthesised in hospitals using simple kit vials, firmly establishing 99mTc as the staple medical radionuclide. In general, the close cooperation of clinicians, physicists, engineers, biologists and chemists identifies capabilities, conceives challenges, discovers solutions and applies them in the clinic. Each discipline produces innovations that in turn drive innovations in the others. This chapter explores the past and future direction of radiopharmaceutical development.

Original language	English
Title of host publication	A History of Radionuclide Studies in the UK: 50th Anniversary of the British Nuclear Medicine Society
Publisher	Springer International Publishing Switzerland
Pages	141-148
Number of pages	8
ISBN (Electronic)	9783319286242
ISBN (Print)	9783319286235
DOIs	https://doi.org/10.1007/978-3-319-28624-2_19
Publication status	E-pub ahead of print - 10 Mar 2016

Access to Document

10.1007/978-3-319-28624-2_19Licence: CC BY-NC

The future direction of radiopharmaceutical_BLOWER_Publishedonline10March2016_GOLD VoR (CC BY-NC)Final published version, 317 KBLicence: CC BY-NC

Cite this

@inbook{7b0e84e60e0243a4a75af971af172de4,

title = "The future direction of radiopharmaceutical development",

abstract = "The first use in humans of 24Na-sodium chloride by Hamilton and Stone in 1936 began a story in which 131I-iodide became established for treating thyroid disease and radionuclide imaging became routine in hospitals. Later a range of 99mTc-radiotracers quickly became available and they were easily synthesised in hospitals using simple kit vials, firmly establishing 99mTc as the staple medical radionuclide. In general, the close cooperation of clinicians, physicists, engineers, biologists and chemists identifies capabilities, conceives challenges, discovers solutions and applies them in the clinic. Each discipline produces innovations that in turn drive innovations in the others. This chapter explores the past and future direction of radiopharmaceutical development.",

author = "Blower, {Philip J.}",

year = "2016",

month = mar,

day = "10",

doi = "10.1007/978-3-319-28624-2_19",

language = "English",

isbn = "9783319286235",

pages = "141--148",

booktitle = "A History of Radionuclide Studies in the UK: 50th Anniversary of the British Nuclear Medicine Society",

publisher = "Springer International Publishing Switzerland",

}

TY - CHAP

T1 - The future direction of radiopharmaceutical development

AU - Blower, Philip J.

PY - 2016/3/10

Y1 - 2016/3/10

N2 - The first use in humans of 24Na-sodium chloride by Hamilton and Stone in 1936 began a story in which 131I-iodide became established for treating thyroid disease and radionuclide imaging became routine in hospitals. Later a range of 99mTc-radiotracers quickly became available and they were easily synthesised in hospitals using simple kit vials, firmly establishing 99mTc as the staple medical radionuclide. In general, the close cooperation of clinicians, physicists, engineers, biologists and chemists identifies capabilities, conceives challenges, discovers solutions and applies them in the clinic. Each discipline produces innovations that in turn drive innovations in the others. This chapter explores the past and future direction of radiopharmaceutical development.

AB - The first use in humans of 24Na-sodium chloride by Hamilton and Stone in 1936 began a story in which 131I-iodide became established for treating thyroid disease and radionuclide imaging became routine in hospitals. Later a range of 99mTc-radiotracers quickly became available and they were easily synthesised in hospitals using simple kit vials, firmly establishing 99mTc as the staple medical radionuclide. In general, the close cooperation of clinicians, physicists, engineers, biologists and chemists identifies capabilities, conceives challenges, discovers solutions and applies them in the clinic. Each discipline produces innovations that in turn drive innovations in the others. This chapter explores the past and future direction of radiopharmaceutical development.

UR - http://www.scopus.com/inward/record.url?scp=85026463804&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-28624-2_19

DO - 10.1007/978-3-319-28624-2_19

M3 - Chapter

AN - SCOPUS:85026463804

SN - 9783319286235

SP - 141

EP - 148

BT - A History of Radionuclide Studies in the UK: 50th Anniversary of the British Nuclear Medicine Society

PB - Springer International Publishing Switzerland

ER -

The future direction of radiopharmaceutical development

Abstract

Access to Document

Other files and links

Fingerprint

Cite this